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ABSTRACT 
A major clinical finding in dementia with Lewy bodies (DLB) is the presence of well-
formed visual hallucinations and an associated finding is the presence of glucose 
hypometabolism and reduced perfusion on imaging of the primary visual cortex. We 
therefore sought to determine the underlying basis for these changes in order to aid 
understanding the involvement of the visual system in the generation of recurrent 
complex visual hallucinations (RCVH) which are a characteristic feature of DLB. 
Pathological investigation showed an absence of alpha-synuclein pathology or 
neurofibrillary tangles in primary visual cortex but the presence of mild alpha-
synuclein pathology and tangles in the adjacent secondary visual cortex. This 
contrasted with Alzheimer’s disease (AD) where both primary and secondary visual 
cortex showed significant neurofibrillary tangle burden. Stereological analysis of 
neurones in primary visual cortex showed no change in density or volume in DLB, but 
a reduction in neuronal volumes without density change in AD indicating atrophy. 
GAD65/67 immunohistochemistry showed no reduction in interneurone number in 
DLB suggesting that GABAergic neurones were essentially intact. However microarray 
analysis of primary visual cortex in DLB showed an altered neuropeptide profile and 
changes in GABAergic markers suggesting altered GABAergic neuronal function.. In 
addition loss of post synaptic GABA markers such as Gephyrin, GABARAP, and Kif5A 
were also present along with decreased synaptophysin suggesting altered synaptic 
activity within the primary visual cortex. Post synaptic glutamatergic neuronal 
signalling was also affected given a reduction in vesicular glutamate transporter 
protein expression and PSD-95 expression. The changes identified appear to support 
the concept that decreased inhibitory neurone activity and enhanced glutamatergic 
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neuronal excitability occur in the primary visual cortex in DLB and we speculate that 
this may contribute to the RCVH. If so, these results suggest it may be possible to 
reduce RCVH through targeting of GABA neurones using selective GABAergic agonists. 
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 Introduction 
Dementia with Lewy bodies (DLB) accounts for up to 20% of all dementia cases 
at autopsy [1]. Clinically DLB is associated with at least two of the following three core 
clinical features: recurrent complex visual hallucinations (RCVH), fluctuating cognition 
and parkinsonism [2] or one of these plus one supportive feature (from: neuroleptic 
sensitivity, abnormal dopaminergic imaging of striatum, or rapid eye movement sleep 
behaviour disorder) [3]. It is the presence of RCVH however, that has been suggested 
to be one of the most characteristic of the disorder and their treatment can be 
complicated by severe neuroleptic sensitivity [2] .  
 
The RCVH in DLB are described as being well formed and involve animals, 
people, and objects [4] and show some similarities with the visual hallucinations seen 
in Charles-Bonnet syndrome and those that occur following occipital infarction [5, 6]. 
Illusions and misperceptions are also experienced, and the occurrence of passage and 
presence hallucinations are also common, as with Parkinson’s disease (PD) and 
Parkinson’s disease with dementia (PDD) [7-9]. Whilst RCVH are one of the core clinical 
symptoms of DLB, their aetiological basis is essentially unknown.  DLB subjects show, 
for example, hypoperfusion and glucose hypometabolism in the medial occipital lobe 
including the primary and secondary visual cortex [12-14] and this associates with the 
visuoperceptual problems which are common to both DLB and PDD [15]. RCVH have 
been suggested to be due to cortical atrophy, although most neuroradiological studies 
do not find significant atrophy of the medial occipital cortex in DLB or in PD or PDD [16-
21]. Whilst there appears to be involvement of the lateral occipital cortex in DLB [13, 
14], the only significant pathology reported is spongiform change and gliosis in the 
Commented [JT1]: I would focus on perhaps that they cause 
patient and carer distress and are a marker for early nursing home 
admission. 
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medial occipital white matter [22], although this  has not been observed in all studies 
[23].  
 
Ocular pathology may also contribute but these are common in elderly individuals 
where  clouding, increased central and peripheral corneal opacity, and macular 
degeneration being typical [10, 24]. Related to these ocular changes with age there 
are also changes in visual perception with decreased capacity to identify motion in 
spatial suppression tasks [25], and in motion perception [26, 27], along with reduced 
acuity [28] and ability to determine images in the peripheral fields [29]. These 
changes are accompanied by problems associated with visual image processing 
including altered saccadic eye movements. Visual imagery appears reduced in normal 
ageing with a decreased ability to respond to cues with decreased image generation 
as a result of decreased ability of cortical visual association areas [30]. This is also 
seen with simple image generation [31] and the prefrontal cortex may mediate this 
effect with atrophy leading to reduced image manipulation and generation [32]. The 
interaction between reduced higher cortical and altered proximal visual system 
mechanisms associated with ageing may therefore contribute to the RCVH seen in 
DLB. 
 
The well-formed nature of RCVH in DLB suggests that the ventral visual stream [33, 
34] is affected. The ventral stream from the primary visual cortex projects to the 
temporal lobe, including the amygdala. These areas contain relatively high numbers 
of LB and it has been speculated that these contribute to RCVH [35, 36] although no 
differences between hallucinating and non-hallucinating cases have been observed. 
Commented [JT2]: This section seems a little over detailed for 
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Nevetheless  high densities in parahippocampal gyrus have been suggested to relate 
to early development of RCVH [23, 24].  Alpha-synuclein pathology in the retina [37] 
and cholinergic dysfunction [38] have been observed indicating that pathological 
changes in the eye and biochemical changes in the primary visual cortex may 
contribute to RCVH [39].  
 
Since the possible changes in DLB which could contribute to RCVH do not stand alone 
but are part of the highly complex visual system, the question arises as to what are 
the molecular substrates of RCVH in DLB? Given the paucity of information on 
pathology in the primary visual cortex in DLB, but with the presence of a marked and 
specific hypometabolic deficit in this region [13, 40], it is certainly possible that 
biochemical abnormalities in the visual cortex contribute to RCVH. We therefore 
explored this issue and describe here the analysis of the molecular changes in the 
primary visual cortex in DLB using a combination of pathology and stereology to 
identify pathological and neuronal involvement, coupled with transcriptomic analysis 
of RNA and complimentary protein determination to determine the biochemical 
systems involved.   
Commented [JT3]: Where – eye or brain? From the reference it 
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Clinical Samples 
All procedures were approved by the Local Research Ethics Committee and tissue was 
obtained from the Newcastle Brain Tissue Resource (NBTR), a UK Human Tissue 
Authority approved research tissue bank. The DLB and AD cases were from a local 
prospective clinical study, with participants having clinical assessments repeated 
annually until death and agreeing to donate tissue for research purposes. Clinical 
diagnoses of DLB and AD were made according to international consensus criteria [3] 
and NINCDS ADRDA criteria [41] respectively.  Healthy control subjects were obtained 
from NBTR and all such cases had had thorough case note review to confirm they did 
not have cognitive impairment and did have normal everyday function at time of 
death.  All cases had neuropathological confirmation of either DLB, AD, or were 
neuropathologically normal according to established criteria [3, 42-44]. Cases of DLB 
had the presence of visual hallucinations documented or were without any 
documented RCVH (1 case), whilst AD cases showed an absence of any prior history 
of visual hallucinations (See Table 1). Tissue was obtained at post mortem, and the 
delay from death to freezing and fixation was noted. Tissue from the left hemisphere 
was rapidly frozen at -80oC using pre-cooled copper blocks as approximately 1cm 
thick slices and stored at -80oC until use. The right hemisphere was fixed in 10% 
formalin and processed by paraffin wax embedding. A 1cm-thick slab of fixed tissue of 
the occipital lobe was cut into a series of 25 x 40-µm-thick tissue slices from a pre-
defined paraffin-embedded coronal block containing the relevant portion of the 
middle of the primary visual cortex. Three of the 25 sections were sampled at equally 
spaced intervals (every eight sections) and stained with cresyl fast violet. The quality 
of each section was checked for consistency and the slides coded (CMM) to ensure 
   
that all analysis was carried out blind to diagnosis. The layers of the primary visual 
cortex were delineated in accordance with previous literature [45]. All measurements 
were taken from the cortical strip directly surrounding the Calcarine sulcus.  
Additional paraffin sections (6-10μm) were taken for pathological investigation and 
stained for myelin (Loyez stain), and with haematoxylin and eosin to show general 
structure. Immunohistochemical investigations of pathology used a standard ABC 
peroxidise method using anti-α-synuclein, anti-Amyloid β peptide , and anti-
phosphorylated tau  and quantified using a standardised morphometric approach [46, 
47] (antibodies details given in Supplementary Table 3).  
 
Stereology 
Neuronal density and volume was estimated within layers of the primary visual cortex 
using analysis software (Stereologer, Chester, MD, USA) to apply the optical disector 
[48, 49] and rotator [50] methods to obtain the density and volume estimates 
respectively, as in our previous studies [51-53]. Neurones were identified using 
standardised criteria: the presence of a Nissl-stained cytoplasm, pale nucleus and 
single identifiable nucleolus in cells that were not spherical unlike glial cells.  The 
sections were viewed in oil using a Zeiss Photomicroscope at x 100 objective and a 
numerical aperture of 1.25. The microscope was attached to a JVC colour video 
camera TK-C1360B (JVC UK Ltd, London, UK), a motorised x- and y-axis stage accurate 
to 1 μm (Optiscan ES110, Prior Scientific Instruments Ltd, Cambridge, UK) and a 
Heidenhain z-axis depth gauge accurate to 0.5 μm (Heidenhain GB Ltd, London, UK) 
to ensure accurate measurement of disector depth.  
 
   
Based on our previous investigations [51-53], a random sampling strategy was used 
and estimates were conducted using one disector field per field of view and over 120 
counts were made per layer examined in each subject to ensure precise estimates. 
Each disector frame measured 50 µm long, 50 µm wide and 15 µm deep, with a guard 
area of at least 4 µm taken (average µm) above and below the 3-D disector box, 
dependent on section thickness measurement. The mean coefficient of error (CE) for 
the overall neuronal and glial estimates were calculated using the Gundersen-Jensen 
method [54], as previously [51-53], and showed  that the mean CE for neuronal 
volume and density reached an acceptable level of precision in all layers in all cases 
measured (P<0.15) [54]. There was no significant difference in demographic, clinical 
and histopathological information on the study sample, as summarised in Table 1. 
There were no significant differences between the groups in age, gender, tissue pH, 
duration of tissue fixation (d.f.= 25, P<0.05 for all measures), or post-mortem interval.  
Mean (±SD) section thickness across all layers was comparable (d.f. = 25, p=0.70) 
between control (31.82 [1.00] µm), AD (31.58 [0.79] µm) or DLB (31.89 [0.37] µm) 
groups after processing. 
 
RNA isolation 
The primary visual cortex was identified in blocks of snap frozen tissue and 
approximately 50mg of grey matter was dissected at -20oC from a second series of 14 
DLB, 13 control, and 15 AD cases rated as previously (see Supplementary Table 1) and 
placed in 5 – 10 volumes of pre-cooled RNAlater solution (Ambion) and stored at -
80ºC. Tissue was removed from RNAlater and rapidly homogenised in TRI- Reagent 
   
(Ambion) and stored at -80ºC. RNA was extracted using a spin column method as per 
the manufacturer’s instructions (Ribopure, Ambion, Warrington, UK) and 1ug of RNA 
was DNase-treated (Turbo-DNAase free, Ambion).  The RNA concentration was 
determined using a Nanodrop ND 1000 Spectrophotometer (Nanodrop Technologies) 
and RNA integrity number (RIN) examined with an Agilent 2100 Bioanalyzer RNA 6000 
Nano Assay (Agilent Technologies) according to the manufacturer’s instructions. 
Microarray Analysis 
Control (n = 12) and DLB (n = 12) total RNA samples were selected from the second 
group on the basis of tissue pH (>6.0) and RIN value (>6.0) (see Supplementary Table 
1) and were analysed using Illumina Human-6 v2 BeadChips with approximately 
48,000 transcript probes per chip using a GLP certified facility (Aros, Brensby, 
Denmark). Data was imported into R, log2 transformed using a Variance Stabilizing 
Transformation [55] and Robust Spline Normalisation algorithm designed for 
Beadarray data [56]. Following removal of failed samples and outliers using 
hierarchical clustering, significantly altered transcripts were identified in the limma 
package [57] and differentially expressed genes identified by applying cut-offs  of p-
Value <0.05 (Benjamini-Hochberg FDR correction [58]), and an absolute fold-change 
of greater than 2. To identify systems that may be altered/associated with DLB in the 
primary visual cortex we used Gene Ontology (GO) [59] to identify biological process, 
molecular function and cellular component annotations using the GOstats package to 
test gene lists for over-represented terms [60] and also Kyoto Encyclopaedia of Genes 
and Genomes (KEGG)  biochemical pathways  [61]. 
 
   
q-RT-PCR 
Reverse transcription of RNA was performed on 1µg of total RNA using oligo(dT)12-18 
primer (Invitrogen), SupeRNase Inhibitor (Ambion), and Superscript III Reverse 
Transcriptase at 50oC and samples stored at -80ºC until use. Semi-quantitative RT-PCR 
was performed in triplicate using Taqman® assays (see Supplementary Table 2; 
Applied Biosystems) using Taqman® Universal PCR Master Mix (Applied Biosystems). 
A total of 35 different brain tissue samples with total RNA of RIN>6.0 were analysed 
by q-RT-PCR with 11 control, 12 DLB, and 12 AD subjects used. ABI PRISM® Sequence 
Detection System software was used to generate 2-ΔΔCT values based on the 
comparative CT method with GAPDH mRNA as a reference [62, 63]. To compare the 
relative gene expression, a Mann Whitney test was carried out using 2-ΔΔCT values with 
significance level of p < 0.05.  
Protein Determination 
Tissue blocks of the occipital lobe were brought to -20oC in a freezing cabinet and the 
primary visual cortex identified. Primary visual cortex tissue and a small amount of 
underlying white matter were isolated using a pre-cooled scalpel (see case details, 
Supplementary Table 1). Extraction was performed by homogenising 100-150mg of 
tissue using a rotor stator type homogeniser in ice cold lysis buffer containing 0.2M 
tetraethyl ammonium bicarbonate, pH 7.2 (TEAB; Sigma), 1mM EDTA, and  protease 
inhibitor tablets (Complete, Roche) and samples stored at -80°C. Samples were 
thawed, made to 0.02% sodium dodecyl sulphate and sonicated on ice in a sonicating 
water bath for 20 minutes before protein quantitation was performed using a BCA 
   
Protein Assay kit (Pierce, Rockford, IL). 
 
Proteins (5-20µg of protein per sample) were separated using NuPAGE 12% Bis-Tris 
gels (Invitrogen) with 1x SDS NuPAGE MOPS Running Buffer containing 0.248% 
NuPAGE Antioxidant (Invitrogen). Proteins in the gel were transferred to 
nitrocellulose membranes using an iBlot device (Invitrogen).  Membranes were 
stained with Ponceau S solution (Sigma) to ensure equal protein loading, destained 
with 1x Tris-Buffered Saline (TBS) 0.2% Tween 20, and stored in 1x TBS 0.2% Tween 
20 at 4oC overnight. The membrane was incubated with 5% dried milk in 1x TBS 0.2% 
Tween 20 for 30 minutes at room temperature to block non-specific protein binding 
sites and incubated overnight with primary antibody (see supplementary Table 3) 
diluted in 5% dried milk in 1x TBS 0.2% Tween 20 at 4oC with agitation. Membranes 
were then washed for 10 minute intervals 3 times with 1x TBS 0.2% Tween 20 and 
incubated a further 30 minutes with the appropriate horseradish peroxidase 
conjugated secondary antibody at room temperature. Membranes were washed for 1 
hour with four washes of TBS 0.2% Tween 20 then proteins visualised by Enhanced 
Chemiluminescence (GE, Amersham, Bucks, UK) and detected using x-ray film (Fuji, 
Fisher Scientific, UK). Protein bands were subsequently quantified using Image-J 
(NIH). Target protein expression was determined by normalising to GAPDH protein 
expression. 
 
Validated commercial ELISA assays against BDNF (Promega Corporation, Madison, WI, 
USA), somatostatin, and neuropeptide Y (Cambridge Bioscience, Cambridge UK) were 
   
used according to the manufacturer’s instructions. Samples of BA17 tissue 
homogenates were thawed on ice and centrifuged at 16,000 x g for 20 minutes at 4oC 
and the supernatant collected and diluted 1:20-1:50 in assay diluent buffer and 
applied to prepared assay plates. Samples were read along with standards using a 
Biotek Synergy Plate Reader. Protein in supernatant samples was determined using a 
BCA Protein Assay kit (Pierce, Rockford, IL) and specific peptide levels expressed as ng 
or pg peptide/mg protein. 
Statistical Analysis 
Analysis of pathology and stereology data involved analysis of variance (ANOVA) with 
pairwise comparison of differences and Bonferroni correction for multiple 
comparisons . PCR data was analysed using Mann Whitney U tests since the data 
were not normally distributed and protein data were analysed initially using Levine’s 
f-test to determine homogeneity of variance and differences using two-way unpaired 
t-tests. In all cases, P<0.05 was considered significant. 
 
Results 
Pathology 
Pathological investigation of the primary visual cortex in relation to RCVH, showed no 
evidence of α-synuclein deposition as Lewy bodies or Lewy neurites within primary 
visual cortex in any DLB case, with some evidence of α-synuclein deposition in BA18 
as Lewy neurites in DLB cases, and increased deposition as Lewy neurites and 
occasional Lewy Bodies in lateral occipital cortex (see figure 1). The mean intensity of 
α-synuclein staining in three occipital regions was recorded for primary visual cortex, 
secondary visual cortex and also lateral occipital cortex. No difference was seen in 
   
staining intensity between DLB, AD and control cases for overall α-synuclein staining 
intensity. A difference in the intensity of staining between areas was seen for BA17, 
BA18 and BA37 within the DLB group (ANOVA: F(2,42)=7.444, p=.002) with 
significantly more staining in secondary visual cortex (114.49 ± 2.84, P=0.038) and in 
BA37 (119.10 ± 3.05, P=0.001) compared to primary visual cortex (104.99 ± 1.86).  A 
similar significant difference between the areas was also seen in the AD group 
(ANOVA: F=(2,147)=32.275, P<0.001). There were no statistically significant 
differences between the staining in secondary visual cortex and lateral occipital 
cortex in AD (P=0.440). There was no statistically significant difference between the 
three areas in DLB compared to AD (ANOVA: F=(2,147)=1.328, P=0.268).  Transcripts 
for α-synuclein mRNA were lower (37%) in DLB than controls although this was not 
significant, and similarly protein analysis of α-synuclein monomer (18kDa) showed no 
significant change in expression in DLB (p = 0.16), with comparable levels of 
expression in control and AD subjects (see Table 2), consistent with previous studies 
[64, 65].   
 
Assessment of amyloid-β and Tau pathology in the primary visual cortex in AD 
showed a  high level of amyloid-β pathology in the form of senile plaque and diffuse 
amyloid-β deposition, which was significantly higher than in controls and also higher 
than in DLB (p<0.005 vs control; p<0.05 vs DLB, see and Supplementary Figure 1). 
Amyloid-β pathology was found in the occipital cortex in DLB, but was not higher than 
in cognitively normal controls. No changes in APP mRNA expression were seen in the 
primary visual cortex using q-RT-PCR in either DLB or AD (see Table 2). Tau pathology 
as assessed by AT8 immunostaining in the occipital lobe in AD cases was present as 
   
neurofibrillary tangles and neuropil threads and showed high densities in the primary 
visual cortex  but was absent from control and DLB cases (p<0.05 vs control; p<0.05 vs 
DLB see Supplementary Figure 1). No changes in MAPT (Tau) mRNA expression were 
seen in the primary visual cortex using q-RT-PCR in DLB, although MAPT mRNA levels 
were higher in AD cases compared to controls though not significantly (see Table 2). 
 
Stereology 
Since neurodegenerative pathology in the primary visual cortex in DLB was not 
significantly different from normal elderly control individuals, neuronal densities were 
determined in the primary visual cortex. There was no significant difference in 
neuronal density in any layer of the primary visual cortex between control and DLB or 
AD groups after multiple comparison analysis (Figure 2). However, there was a 
significant reduction in neuronal volume in layer 4a in the AD group (P=0.042; see 
Figure 3) in comparison to the control group. Furthermore, a significant reduction in 
neuronal volume in the AD (P=0.043) versus control group was found across all layers 
when combined. No significant changes were found in neuronal volume in the DLB 
group against control or AD groups in any layer of the primary visual cortex. Similarly, 
since hypoperfusion and hypometabolism is a feature of DLB occipital cortex [13], we 
determined the presence of capillary density in primary visual cortex in DLB using 
Glut-1 staining. No alterations in capillary density were observed in either DLB or AD 
brain compared to age matched controls (not shown) suggesting hypoperfusion and 
hypometabolism is not associated with altered capillary density.  
 
Microarray 
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Owing to the lack of significant α-synuclein pathology or of major amyloid-β or Tau 
deposition in DLB and any significant cell loss in the primary visual cortex in DLB, 
whole genome microarrays were used to determine the changes that might underlie 
any biochemical abnormality associated with hypoperfusion and hypometabolism. 
Seventy three genes were seen to be significantly altered in the primary visual cortex 
using the described cut-offs (see Figure 4; Table 4). Several systems were identified as 
altered in the primary visual cortex and linked with DLB most notably in cellular 
signalling, synaptic transmission, and vesicle transport (see Supplementary Table 4). 
One finding associated with the microarray data was the presence of RNA changes for 
neuropeptide molecules such as proenkephalin (PENK), tachykinin (TAC1) and 
prodynorphin (PDYN) transcripts (see Table 4). These neuropeptides which are 
primarily expressed by specific interneurone populations suggests that there may be 
GABAergic dysfunction associated with the primary visual cortex in DLB, and this was 
underlined by the presence of other GABAergic markers in this patient group, most 
notably GAD2 (GAD65) and SLC32A1. Using GAD65/67 as a marker of total number of 
GABAergic cells, no alteration in total counts of cells was seen in the cortex for 
GAD65/67 stained neurons for DLB or AD in either primary visual (ANOVA: 
F(2,23)=0.389, p=0.682) or secondary visual cortices (ANOVA: F(2,23)=1.184, p=0.186; 
see Table 5) and this was paralleled by an absence of any significant change in GAD1 
mRNA transcripts for DLB relative to control, although a slight but significant 
reduction GAD1 was seen in AD (p = 0.0337; Table 6), though AD and DLB groups 
were comparable. Similarly, there was no alteration in GAD65 or GAD67 protein 
determined by western blotting in either DLB or AD (see Table 6) suggesting that 
   
GABAergic neurones are still present but potentially dysfunctional based on peptide 
markers.  
 
To explore the possibility that GABAergic neurones were either degenerate or 
dysfunctional in specific neuronal subtypes, numbers of calcium binding protein 
containing neurones were quantified to determine if cell loss was selective. We 
studied the levels of parvalbumin (PVALB, mRNA; PVALB, protein), a marker of the 
fast spiking basket and chandelier neurones that provide major inhibitory inputs onto 
soma and axons of pyramidal neurones. PVALB mRNA was significantly reduced in 
DLB (p = 0.0035) but was also significantly increased in AD (p = 0.0002) (Table 6). 
These changes in PVALB mRNA were also complemented by changes in PVALB protein 
with a reduction of approximately 15% in DLB (p=0.033) and an increase in AD of 
approximately 25% (p=0.0005). Given the absence of any reduction in overall 
GABAergic neurones (see Table 5), Parvalbumin, D-28 Calbindin and Calretinin 
neuronal density in the primary visual cortex were investigated using stereological 
methods however, no significant change in the density of these neuronal markers in 
either DLB or AD were seen (see Figure 5) suggesting that whilst the neurones may 
show altered marker profiles, their density is unchanged.   To further investigate this 
altered marker profile protein levels for other neuropeptides within the primary 
visual cortex in DLB were assessed. Neuropeptide Y levels were increased on ELISA 
analysis in DLB by 15% although not significantly (p=0.22) and in AD NPY was 
increased by approximately 20% (p=0.027) (see Table 6). Somatostatin levels in 
primary visual cortex were increased by 15% in DLB (p=0.40) and by 40% in AD 
(p=0.09). 
   
 
To determine if these neuropeptide changes were associated with alterations in other 
GABAergic markers, levels of several proteins involved in GABA neurotransmission 
were determined. The GABAergic post-synaptic marker GABARAP involved in GABA 
(A) receptor clustering/transport [66, 67] showed reduced expression of the 17kDa 
GABARAP isoform of approximately 40% (p< 0.001) and of the 14kDa GABARAP 
isoform of approximately 30% (p<0.001) in DLB: in AD the 17kDa isoform was reduced 
to a lesser extent by about 15% (p<0.001) and the 14kDa isoform by 20% (p<0.001) 
when compared to controls (see Table 6). The GABA motor protein Kif5A showed a 
trend towards reduction in DLB (p=0.06), but no change in AD. Gephyrin, a post 
synaptic GABA-A associated protein which anchors GABA-ergic and glycinergic 
receptors to the post-synaptic cytoskeleton [68, 69], showed a significant reduction of 
approximately 25% in DLB (p<0.001) and in AD a reduction of about 20% (p<0.0001). 
Using ionotropic GABA A1 receptor subunit as an additional marker of receptor 
activity, showed no significant change in either DLB or AD (see Table 6).  
 
Since alterations of GABAergic activity may lead to altered excitation, a series of 
glutamatergic synaptic markers were assessed (see Table 7). Using an anti-VGlut1 
(SLC17A7) antibody as a marker of cortical input into the primary visual cortex, we 
demonstrated bands from 59-61 kDa, reflecting VGlut1 isoforms ranging from 59.3 to 
61.3 kDa. DLB cases were not significantly different to controls in VGlut1 isoform 1 
(61.3kDa; p=0.14), with AD cases showing a trend towards reduction (p=0.08). DLB 
cases were also not significantly different to controls in VGlut1 isoform 2 (59.3kDa; 
p=0.72) and AD cases were also not significantly different to controls (p=0.78). 
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Similarly the metabotropic glutamate receptor mGluR1 was also unaltered in DLB. 
The reduction in glutamate synaptic markers in DLB was not associated with a loss of 
ionotropic AMPA glutamate receptor (GluR1/GRIA1) mRNA which was unchanged in 
DLB primary visual cortex.  As a marker of neural activity we observed a selective 
reduction in BDNF mRNA in the primary visual cortex in DLB cases (p<0.05; Table 7) 
but were unable to detect BDNF protein in any samples using a specific ELISA. Whilst 
variable, there was a trend towards reduction of the post-synaptic excitatory scaffold 
protein DLG4 (PSD-95) mRNA in DLB, and in AD this reduction was significant (p<0.05; 
see Table 7). PSD95 protein determination however showed a marked 50% decrease 
in DLB compared to controls (p=0.0002), whilst AD cases showed no significant 
change in PSD95 (p=0.96) in primary visual cortex. In line with PSD-95 findings, we 
identified a selective reduction of 43% of the growth cone marker GAP43 in DLB 
primary visual cortex (p=0.0005) whilst AD cases showed no significant change in 
GAP43 (p=0.11). As markers of synaptic neurotransmission we determined 
synaptophysin as a marker for presynaptic vesicular membranes and SNAP25 levels as 
a marker of presynaptic vesicles. Synaptophysin showed a marked and significant 44% 
decrease in DLB cases (p<0.00001) and also a lesser 22% decrease in AD cases 
(p=0.01). DLB cases however, showed no significant difference in SNAP25 expression 
compared to controls (p=0.43), and similarly AD cases also showed no significant 
difference in SNAP25 expression compared to controls (p=0.13) indicating general 
exocytosis was unaltered. 
Discussion 
Visual hallucinations and other abnormal visual percepts have a complex aetiology 
with the potential involvement of multiple systems including the eye, primary visual 
   
cortex, and higher order brain regions including the inferior and medial temporal lobe 
and frontal cortex [5, 6, 70]. A major feature of DLB is the presence of marked and 
well-formed RCVH [4] which may be a result of abnormalities in the ventral visual 
stream due to the object based nature of RCVH [34]. This study showed an absence of 
demonstrable neuropathological changes in primary visual cortex with no significant 
evidence of Lewy body or AD type pathology or change in neurone density or volume 
in DLB. This suggests that occipital hypoperfusion and hypometabolism seen in 
conjunction with RCVH are associated with dysfunction rather than 
neurodegeneration in the primary visual cortex. In AD, however, the presence of 
major pathology and also of neurone atrophy, may indicate that the primary visual 
cortex is simply less responsive to stimulation, and consequently RCVH in AD are not 
common findings due to neurodegeneration. Because of the absence of pathology in 
DLB, we used a transcriptomic approach to determine what gene expression changes 
underpin the possible changes in the primary visual cortex. The current findings 
indicate that there is an alteration in the profile of several GABA and neuropeptide 
markers which are suggestive of changes in the interneurone pool. Whilst the 
microarray finding shows GABAergic changes, the major interneurone population is 
still intact based on the calcium binding protein profile staining, underscoring that 
dysfunction rather than degeneration occurs in the primary visual cortex in DLB.  
Although the transcriptomic and morphological changes in the primary visual cortex 
point towards dysfunction, the underlying changes in neurotransmission that regulate 
this region require definition and here it would appear that specific synaptic changes 
in both inhibitory interneurones and also excitatory neurones were present.  
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The changes in GABAergic interneurones and excitatory neurones suggest that there 
may be parallels with the changes seen in the primary visual cortex following dark 
rearing or reduced visual input in animals [71, 72]. Here, reduced input leads typically 
to changes in the function of inhibitory interneurones in the primary visual cortex 
with a reduced expression of parvalbumin in fast spiking interneurones [73]. There 
are also relatively specific changes in the primary visual cortex following reduced 
stimulation with an increased turnover of synaptic boutons of interneurones both 
acutely and chronically [74-77]. While much of this work has been conducted in the 
mouse, primate work also suggests a loss of GABAergic interneurone function 
following decreased input [76, 78] and acutely in man  [79]and this degradation of 
function also occurs in primary visual cortex in normally aged monkeys and can be 
rescued by GABAergic agonists [80]. The reduced expression of GABAergic markers 
such as Gephyrin and GABARAP may be an indication of the eye pathology frequently 
found in DLB patients and ageing [10, 15]. DLB patients frequently show visuo- 
perceptual impairments and the presence of ocular pathology may reduce input to 
the primary visual cortex [15, 81]. Conversely, environmental enrichment in mice 
leads to enhanced BDNF expression in the primary visual cortex [82] which contrasts 
with the decreased BDNF mRNA expression seen in DLB cases in the current study 
(see Table 6, 7). Visual input regulates the expression of BDNF mRNA [83] in 
glutamatergic neurones with reduction of BDNF leading to altered GABAergic 
transmission [84] and development of ocular dominance columns [85] which may 
suggest that the reduced protein expression activity seen in the current study is a 
consequence of decreased visual input. This may be a stereotyped response of 
primary visual cortex in an attempt to increase excitation by decreasing inhibition, 
   
and would support the suggestion of decreased inhibition as a factor in RCVH in DLB 
[86]. 
 
The results here suggest reduced connectivity in the primary visual cortex of DLB with 
a relatively selective reduction of synaptic proteins and genes, for example 
synaptophysin, α-synuclein, and PSD95, compared to the atrophy associated changes 
seen with AD. PSD95 is specifically associated with the post-synaptic membrane at 
excitatory synapses [87, 88] indicating that transmission from the pre-synaptic 
terminal to excitatory post-synaptic terminal is impaired along efferent connections 
(i.e. from the LGN to the primary visual cortex). Whilst the major input to the primary 
visual cortex is from the LGN, reciprocal connections do enter from adjacent visual 
cortical areas (secondary visual cortex, etc.) and through secondary visual pathways 
via the pulvinar and so reductions in PSD95 or synaptophysin may represent such 
defects. Using VGlut1 as a marker of cortico-cortical connections, we observed no 
significant reductions in VGlut1 in DLB but observed reductions in VGlut1 in AD where 
there was a general reduction along with atrophy in excitatory neurones (Fig 3) due 
to pathology (e.g. [89, 90]) and increased pathology in secondary visual cortex in 
these neurones [91]. This would indicate that intrinsic and cortical glutamatergic 
synapses are not lost in DLB but that subcortical input from the LGN to the primary 
visual cortex may be impaired. This supports the concept of reduced visual system 
input to the primary visual cortex as being part of the process of generation of RCVH 
in DLB as with other primary visual system lesions [70] and that “bottom up” changes 
are important in RCVH as has been noted for PD [92].  
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These changes in input and GABA neurotransmission may have a clinical correlate 
within the symptomatology of RCVH in DLB. The effects of altered GABA 
neurotransmission may be seen in an increased excitability of pyramidal neurones, 
and this can be observed in DLB where the use of transcranial magnetic stimulation of 
the occipital cortex (occiput) is correlated with increased excitability and the 
generation of RCVH like phosphenes [93] and these changes may be due to decreased 
inhibition. Reduced levels of parvalbumin, such as seen in this study, have been 
suggested to cause altered gamma oscillations within cortical regions whereby the 
gain and modulation of firing of pyramidal neurones is affected [94, 95]. 
Desynchronisation of pyramidal neurones in the primary visual cortex and increased 
excitability may therefore lead abnormal outflow to higher order visual areas which 
appear to show changes in DLB [81] resulting in RCVH. 
 
The presence of reduced visual input into the primary visual cortex in DLB whilst 
being part of the aetiology of RCVH, does suggest that further changes must 
contribute to RCVH. For example, RCVH do not necessarily occur in blind individuals, 
and this raises the possibility that in addition to changes in the primary visual cortex, 
other pathological or biochemical changes are required in order to result in RCVH 
[81]. Clearly there are changes in the retina in DLB and also in PD with loss of 
dopamine and of reduced retinal thickness found in some studies using optical 
coherence tomography which may contribute to the visual impairment and RCVH [11, 
96-99]. Some studies indicate changes in processing associated with retinal changes 
may also occur in PD [100]. Considerable attention has however focussed on changes 
in temporal lobe structures in DLB and also PD in relation to visual hallucinations [7, 
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81]. Pathological correlates have indicated that temporal lobe Lewy bodies correlate 
with the presence of RCVH [35, 101] and that, in PD, elevated Lewy body density in 
the basolateral nucleus of the amygdala and temporal lobe associate with RCVH [24, 
102]. Structurally however, there is relative preservation of the temporal lobe in DLB 
[103] although this may not be the case in PD with RCVH [104]. This is accompanied in 
DLB with decreased connectivity of the temporal lobe [81, 105] and perfusion deficits, 
specifically in the ventral occipitotemporal junction following visual stimulation of 
DLB patients with frequent and more severe RCVH [106].  
 
Our results therefore show that, whilst there is an absence of major pathological 
changes in the primary visual cortex in DLB, this is in the presence of functional 
changes associated with GABAergic neurones. This change may reflect a change to 
the visual input due to reduced visual acuity as a consequence of age related changes 
in the eye. These changes may therefore lead to an inhibitory/excitatory imbalance in 
the primary visual cortex and altered perception of visual stimuli due to changes in 
association cortex. One possibility is that by either treating eye disease or modulation 
of GABAergic inhibition, it may be possible to ameliorate the visual hallucinations 
perceived by DLB patients.  
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